Cell Therapy

The sudden transformation of multiple myeloma from a terminal diagnosis to a manageable chronic condition reached a pivotal junction with the Food and Drug Administration's recent decision to grant full approval to a high-impact combination therapy. By pairing the bispecific antibody Tecvayli with

The meteoric rise of GLP-1 receptor agonists has fundamentally altered the global approach to obesity management, yet the medical community now faces a daunting challenge as patients navigate the "weight loss cliff" that follows the cessation of these powerful pharmaceutical interventions. As

The journey from a single fertilized egg to a functioning human brain is one of nature’s most staggering architectural feats, involving the precise coordination of approximately 170 billion cells. For decades, the prevailing wisdom suggested that cells navigate this complex construction site

Ivan Kairatov is a distinguished biopharma expert with a career built on navigating the intricate crossroads of biotechnology innovation and regulatory strategy. With extensive experience in research and development, he has spent years analyzing how emerging therapies transition from the laboratory

Navigating the High Stakes of Roche’s Latest MS Breakthrough The pharmaceutical industry currently watches with bated breath as Roche’s fenebrutinib, a drug once hailed as the potential gold standard for oral multiple sclerosis (MS) therapy, hits a wall of regulatory uncertainty. While the clinical

The relentless cycle of pricking fingertips and calibrating insulin pumps has defined the existence of millions for decades, yet a silent revolution in bio-electronics is now promising to dismantle this clinical burden forever by merging living tissue with synthetic intelligence. For those living